Viamet Pharmaceuticals aims to price initial public offering of stock

Piper Jaffray, Stifel and Wells Fargo Securities are joint bookrunners

By Devika Patel

Knoxville, Tenn., July 1 – Viamet Pharmaceuticals Holdings LLC plans to price an initial public offering of its common stock with a 30-day greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Piper Jaffray & Co., Stifel Nicolaus & Co. Inc. and Wells Fargo Securities LLC are the joint bookrunning managers.

Proceeds will be used for clinical development, research and development, working capital and other general corporate purposes.

The biopharmaceutical company is based in Durham, N.C. The company intends to list its common stock on the Nasdaq under the symbol “VIAM.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.